Healthcare communications body the HCA appoints new boardPictured above, clockwise from top left: Jo Tayler, Emma Kenny, Edel McCaffrey, Annabelle Sandeman, Alice Choi and Alister Share XHealthcare communications body the HCA appoints new boardhttps://pharmaphorum.com/news/healthcare-communications-hca-board/
Amgen wins latest round in legal tussle over Enbrel patentsAmgen’s reputation as a fearsome adversary in the courtroom remains intact after it won the latest round in Share XAmgen wins latest round in legal tussle over Enbrel patentshttps://pharmaphorum.com/news/amgen-wins-latest-round-in-legal-tussle-over-enbrel-patents/
Novartis pays $678 million to settle US kickback allegationsAnother nail has been hammered into the coffin of the pharma model of providing lavish entertainment and other Share XNovartis pays $678 million to settle US kickback allegationshttps://pharmaphorum.com/news/novartis-pays-678-million-to-settle-us-kickback-allegations/
Indivior ex-CEO could face jail time after opioid convictionThe resignation of Indivior chief executive Shaun Thaxter this week was swiftly followed by a guilty plea – Share XIndivior ex-CEO could face jail time after opioid convictionhttps://pharmaphorum.com/news/indivior-ex-ceo-could-face-jail-time-after-opioid-conviction/
Gilead finally breaks its silence on remdesivir’s priceAfter weeks of speculation, Gilead Sciences has revealed its pricing plans for coronavirus drug remdesivir – and the Share XGilead finally breaks its silence on remdesivir’s pricehttps://pharmaphorum.com/news/gilead-finally-breaks-its-silence-on-remdesivirs-price/
Novartis, Alcon settle US bribery charges with £347 million payoutNovartis and eyecare spinout Alcon have agreed to settle bribery charges brought by the US federal authorities, focused Share XNovartis, Alcon settle US bribery charges with £347 million payouthttps://pharmaphorum.com/news/novartis-alcon-settle-us-bribery-charges-with-347-million-payout/
Bayer agrees $10 billion-plus deal to settle Roundup cancer claimsGerman pharma and chemicals group Bayer may finally have put long-running litigation over its weedkiller Roundup in its Share XBayer agrees $10 billion-plus deal to settle Roundup cancer claimshttps://pharmaphorum.com/news/bayer-agrees-10-billion-plus-deal-to-settle-roundup-cancer-claims/
$2bn deal sees uniQure license haemophilia B gene therapy to CSL BehringUniQure has signed a deal that could be worth over $2 billion with CSL Behring – giving the Share X$2bn deal sees uniQure license haemophilia B gene therapy to CSL Behringhttps://pharmaphorum.com/news/2bn-deal-sees-uniqure-license-haemophilia-b-gene-therapy-to-csl-behring/
Havas Lynx Group promotes Jon Chapman and Paul KinsellaHavas Lynx Group has promoted its executive creative director (ECD) duo of Jon Chapman and Paul Kinsella to Share XHavas Lynx Group promotes Jon Chapman and Paul Kinsellahttps://pharmaphorum.com/news/havas-lynx-group-jon-chapman-paul-kinsella/
